Table 1 Baseline characteristics before propensity score-overlap weighting

Demographics

Age (years), mean ± SD

79 ± 8

77 ± 11

0.21

Male, %

49.5

52.6

0.07

Body mass index (kg/m²), mean ± SD

27 ± 7

28 ± 6

0.14

Creatinine clearance (mL/min), mean ± SD

64 ± 28

73 ± 44

0.24

Systolic blood pressure > 160 mm Hg, %^a

12.1

20.0

0.33

GCS score^b

14 ± 1

14 ± 2

0.00

Anticoagulant indication and medical history, %

Anticoagulant indication, atrial fibrillation

87.9

82.1

0.25

Medical history of heart failure

18.7

23.2

0.15

Medical history of diabetes

28.0

27.4

0.02

Medical history of myocardial infarction

12.1

8.4

0.22

Medical history of stroke

21.5

24.2

0.08

Concomitant use of an antiplatelet

33.6

24.2

0.25

Intracranial hemorrhage characteristics

Initial imaging to reversal start (hours), mean ± SD

2.6 ± 1.8

2.1 ± 1.9

0.30

End of reversal to repeat imaging (hours), mean ± SD

12.4 ± 1.1

8.1 ± 5.1

1.21

Traumatic onset, %

53.3

64.2

0.25

Infratentorial location, %

16.8

12.6

0.19

Size of bleed ≥ 10 mL/mm, %

33.6

14.7

0.59

Single compartment bleed, %

77.6

85.3

0.28

Intracerebral and/or intraventricular bleed, %^c

59.8

48.4

0.25

Subdural bleed, %^c

32.7

40.0

0.17

Subarachnoid bleed, %^c

31.8

27.4

0.12

Reversal agent dosing, %^b

Andexanet alfa

 400 mg bolus + 440 mg infusion

96.3

–

–

 800 mg bolus + 860 mg infusion

3.7

–

–

4F-PCC

 25 units/kg infusion^d

–

74.3

–

 50 units/kg infusion^d

–

25.3

–